Preview

Diagnostic radiology and radiotherapy

Advanced search

DIAGNOSTIC CAPABILITIES OF SPECT/CT IN THE BONE METASTATIC DISEASE DETECTION IN PATIENTS WITH BREAST CANCER AND PROSTATE CANCER

https://doi.org/10.22328/2079-5343-2018-9-2-59-63

Abstract

Purpose. To assess the additional contribution of SPECT/CT, used in conjunction with planar osteoscintigraphy, in bone metastatic disease detection and its effect on the tactics of managing patients with breast cancer and prostate cancer. Materials and methods. The study included 1412 patients with established oncological diagnosis (breast cancer — 844 patients, prostate cancer — 568 patients), to which «whole body» planar osteoscintigraphy, and SPECT/CT were performed. In all patients included in the study, the fact of bone metastatic disease was established by the results of additional imaging techniques and follow up. Results. Bone metastatic disease was detected in 324 (23%) patients and excluded in 1088 (77%). SPECT/CT had higher diagnostic indices than planar osteoscintigraphy. Sensitivity, specificity and accuracy of bone metastatic disease detection of planar osteoscintigraphy were 91%, 71%, 76%, of SPECT/CT, 97%, 93%, 94%, respectively. The additional use of SPECT/CT in the second stage after the planar osteoscintigraphy in 337 (24%) patients from the general group (n=1412) led to a change in the results of the diagnostic test. Conclusions. The additional use of SPECT / CT in the second stage after the planar osteoscintigraphy allows to change the results of the diagnostic test in the evaluation of bone metastatic disease in patients with breast cancer and PCa, which can significantly affect the management tactics of patients.

About the Authors

A. D. Kaprin
Moscow Research Oncology Institute named after P. A. Herzen — branch of National Medical Research Center оf Radiology
Russian Federation


A. A. Kostin
Moscow Research Oncology Institute named after P. A. Herzen — branch of National Medical Research Center оf Radiology
Russian Federation


A. V. Leontyev
Moscow Research Oncology Institute named after P. A. Herzen — branch of National Medical Research Center оf Radiology
Russian Federation


A. I. Khalimon
Moscow Research Oncology Institute named after P. A. Herzen — branch of National Medical Research Center оf Radiology
Russian Federation


T. N. Lazutina
Moscow Research Oncology Institute named after P. A. Herzen — branch of National Medical Research Center оf Radiology
Russian Federation


I. V. Pylova
Moscow Research Oncology Institute named after P. A. Herzen — branch of National Medical Research Center оf Radiology
Russian Federation


M. N. Pheduleyev
Moscow Research Oncology Institute named after P. A. Herzen — branch of National Medical Research Center оf Radiology
Russian Federation


N. A. Rubtsova
Moscow Research Oncology Institute named after P. A. Herzen — branch of National Medical Research Center оf Radiology
Russian Federation


References

1. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность) / под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2017. [Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’) / pod red. A. D. Kaprina, V. V. Starinskogo, G. V. Petrovoj. Moscow, 2017. (In Russ.)].

2. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность) / под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2016. [Zlokachestvennye novoobrazovaniya v Rossii v 2014 godu (zabolevaemost’ i smertnost’) / pod red. A. D. Kaprina, V. V. Starinskogo, G. V. Petrovoj. Moscow, 2016. (In Russ.)].

3. Коган М.И., Лоран О.Б., Петров С.Б. Радикальная хирургия рака предстательной железы. М.: ГЭОТАР-Медиа, 2006. 352 с. [Kogan M.I., Loran O.B., Petrov S.B. Radikal’naya hirurgiya raka predstatel’noj zhelezy. Moscow: Izdatel’stvo GEOTARMedia, 2006. 352 р. (In Russ.)].

4. Хурсевич Н.А., Слонимская Е.М., Усынин Е.А., Юрмазов З.А. Оценка распространенности процесса и выбор тактики лечения при раке предстательной железы с учетом факторов прогноза // Сибирский онкологический журнал. 2003. С. 60–61. [Hursevich N.A., Slonimskaya E.M., Usynin E.A., Yurmazov Z.A. Ocenka rasprostranennosti processa i vybor taktiki lecheniya pri rake predstatel’noj zhelezy s uchetom faktorov prognoza. Sibirskij onkologicheskij zhurnal, 2003, рр. 60–61. (In Russ.)].

5. Манзюк Л.В., Снеговой А.В., Османова Л.И. Зомета в лечении костных метастазов и нарушений минерального обмена у онкологических больных // РМЖ. 2007. № 25. С. 19–24. [Manzyuk L.V., Snegovoj A.V., Osmanova L.I. Zometa v lechenii kostnyh metastazov i narushenij mineral’nogo obmena u onkologicheskih bol’nyh // Rossijskij medicinskij zhurnal, 2007, No 25, рр. 19–24. (In Russ.)].

6. Galasko C.S. The pathological basis for skeletal scintigraphy // J. Bone Joint Surg. Br. Vol. 57. Р. 353–359.

7. Fogelman I., Gnanasegaran G., Van der Wall H. Radionuclide and Hybrid Bone Imaging. Berlin Heidelberg: Springe-Verlag, 2012.


Review

For citations:


Kaprin A.D., Kostin A.A., Leontyev A.V., Khalimon A.I., Lazutina T.N., Pylova I.V., Pheduleyev M.N., Rubtsova N.A. DIAGNOSTIC CAPABILITIES OF SPECT/CT IN THE BONE METASTATIC DISEASE DETECTION IN PATIENTS WITH BREAST CANCER AND PROSTATE CANCER. Diagnostic radiology and radiotherapy. 2018;(2):59-63. (In Russ.) https://doi.org/10.22328/2079-5343-2018-9-2-59-63

Views: 1006


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2079-5343 (Print)